Close Menu

NEW YORK (GenomeWeb) – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.

The Canadian centers include Mount Sinai Hospital's Marvelle Koffler Breast Centre, the Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, and BC Cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.

Apr
21
Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
22
Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).